RxDoctor Payments Data

Steven Hao, MD

Clinical Cardiac Electrophysiology · San Francisco, CANPI 1124019526

Payments from drug & device makers

$73,443in general payments, 2019–2025

Across 113 payments — averaging $649.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$68K
  • Abbott$3K
  • Pfizer$1K
  • Boston Scientific$587
  • Medtronic$276
  • Atricure, Inc.$200
  • plus $227 from 5 others

What the payments were for

  • Consulting fees$59,15081%
  • Speaking & faculty fees$1,1252%
  • Travel & lodging$8,87412%
  • Food & beverage$4,2946%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biosense Webster, Inc.68$67,646
Abbott23$3,381
Pfizer1$1,125
Boston Scientific10$587
Medtronic(2 entities)3$276
Atricure, Inc.2$200
EBR Systems, Inc.1$98
Biotronik Inc.1$41
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)2$41
Amgen1$33
Johnson & Johnson1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$73,443 in reported general payments places this provider in the 60th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$52,011
Medicare patients
90
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$37,442
XareltoRivaroxaban14$16,332
Dofetilide14$3,884
Flecainide Acetate22$520
Metoprolol Succinate24$327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,125$37,44238 claims
Johnson & JohnsonXarelto$16$16,33214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →